Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest Expenses: 2010-2024

Historic Interest Expenses for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $27,353.

  • China Pharma Holdings' Interest Expenses fell 0.66% to $6,798 in Q3 2025 from the same period last year, while for Sep 2025 it was $27,166, marking a year-over-year increase of 111.70%. This contributed to the annual value of $27,353 for FY2024, which is 10.53% down from last year.
  • Per China Pharma Holdings' latest filing, its Interest Expenses stood at $27,353 for FY2024, which was down 10.53% from $30,572 recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Interest Expenses registered a high of $542,001 during FY2021, and its lowest value of $27,353 during FY2024.
  • In the last 3 years, China Pharma Holdings' Interest Expenses had a median value of $30,572 in 2023 and averaged $164,181.
  • In the last 5 years, China Pharma Holdings' Interest Expenses surged by 84.25% in 2021 and then plummeted by 92.97% in 2023.
  • MRY analysis of 5 years shows China Pharma Holdings' Interest Expenses stood at $294,159 in 2020, then skyrocketed by 84.25% to $542,001 in 2021, then fell by 19.81% to $434,619 in 2022, then plummeted by 92.97% to $30,572 in 2023, then fell by 10.53% to $27,353 in 2024.
  • Its last three reported values are $27,353 in FY2024, $30,572 for FY2023, and $434,619 during FY2022.